Search clinical trials for: Zalypsis ( PM00104)

Total 17 results

PharmaMar

Terminated

A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma

Lymphoma | Solid Tumors

United States
PharmaMar

Terminated

Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy

Endometrial Cancer | Uterine Cervical Cancer

United States
PharmaMar

Completed

Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

Ewing's Sarcoma | Primitive Neuroectodermal Tumor (PNET) | Askin's Tumor of the Chest Wall | Extraosseous Ewing's Sarcoma (EOE)

France, United States, Italy
PharmaMar

Completed

Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment

Advanced Colorectal Cancer

United States, Canada, Spain
PharmaMar

Completed

Study of PM060184 in Patients With Advanced Solid Tumors

Solid Tumors

United States
Eli Lilly and Company
ARMO BioSciences

Completed

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (Willow 2)

Healthy Adult Subjects

United States
Eli Lilly and Company
ARMO BioSciences

No longer available

An Expanded Access Program for AM0010 (Pegilodecakin)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Carcinoma | Solid Tumors | Colorectal Carcinoma | Pancreatic Carcinoma
Eli Lilly and Company
ARMO BioSciences

Completed

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants (Willow 3)

Healthy

United States
Eli Lilly and Company
ARMO BioSciences

Completed

A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (Willow 1)

Healthy Adult Subjects

United States
Weill Medical College of Cornell University
Columbia University; Oregon Health and Science University; New York Presbyterian... and other collaborators

Completed

Electronic Prescribing and Electronic Transmission of Discharge Medication Lists

Medication Errors

United States
Eli Lilly and Company
ARMO BioSciences

Terminated

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (Cypress 1)

Non Small Cell Lung Cancer

United States
Alfasigma S.p.A.

Unknown

A Trial to Evaluate the Efficacy and Safety of PMF104 Compared to a Conventional PEG-electrolyte Solution in Children

Bowel Preparation Before Colonoscopy

Italy, Belgium, France
Shyla Cantor
Sytheon Ltd.

Completed

Effects of 2% IDL Lotion on Skin Hydration and Transepidermal Water Loss in Females With Dry Skin

Xerosis Cutis

United States
Eli Lilly and Company
ARMO BioSciences

Terminated

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (Cypress 2)

Non Small Cell Lung Cancer

United States
PharmaMar

Completed

Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors

Solid Tumors

Spain, United States
Eli Lilly and Company
ARMO BioSciences

Completed

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (Sequoia)

Pancreatic Cancer

United States, Belgium, Spain, Poland, Korea, Republic of, Taiwan, Germany, Italy, France, United Kingdom, Austria, Australia, Canada
Eli Lilly and Company
ARMO BioSciences

Active, not recruiting

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (IVY)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Carcinoma | Solid Tumors | Colorectal Carcinoma | Pancreatic Carcinoma

United States

Search clinical trials for: Zalypsis ( PM00104)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations